Abstract

IsoPlexis’ unique new high-plex automated immunoassay applications uniquely enable decentralization of multiplexed and fully automated functional proteomics for accelerated insights. This technology can identify 20-30 cytokines in bulk or at the single-cell level, with only 11 µL of sample per chip, analyzed on the fully automated Isospark and Isolight systems. IsoPlexis’ proteomics platform widens access to advanced insights provided by improved and re-engineered ELISA technology, with a small footprint and end-to-end automation. Recently, high-plex automated immunoassays were utilized in multiple high-impact studies, characterizing CAR-T cell therapies to treat patients with recurrent or refractory B cell malignancies, and in discovering key inflammatory mediators in severe COVID-19.
In this talk we will describe how high-plex automated immunoassays facilitate critical discoveries in immune medicine, accelerating the development of advanced therapeutics across different disciplines such as cancer immunology, cellular therapy, infectious disease and inflammation.